The global insulin syringes market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is expected to accelerate the growth of the market during the forecast period includes a surge in the ageing population and an increased number of diabetic patients globally. Furthermore, some favourable government policies related to insulin syringes are one of the key factors that also fuel the growth of the market. Moreover, a surge in the incidence of obesity and sedentary lifestyles are the factors that are expected to supplement the market growth. However, increased use of insulin pens and high costs of advanced insulin syringes are the factors that could hinder the growth of the market. Emerging markets are anticipated to offer significant growth opportunities for the market players.
The companies are trying to supply essential healthcare insulin syringes, pumps, and others through different modes such as online portals, hospital pharmacies, and emergency medical stores. For instance, in August 2018, Ely Lilly had launched the Diabetes Solution Center program, to provide a free insulin treatment option for financially affected patients who rely on insulin. This is further driving the growth of the market.
Market Coverage
Competitive Landscape: Novo Nordisk A/S, Biocon Ltd, and Becton Dickinson and Co., among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Insulin Syringes Market Report by Segment
By Syringe Size
• 3,10 cc Syringe (0.3 ml)
• ½ cc Syringe (0.5 ml)
• 1 cc Syringe (1 ml)
• Others
By Disease
• Type 1 Diabetes
• Type 2 Diabetes
Global Insulin Syringes Market by Region
North America
Europe
Asia-Pacific
Rest of the World